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1 |  INTRODUCTION
The prognosis for patients with follicular lymphoma (FL) has 
improved significantly since the introduction of rituximab, 
but there is still a subset of patients with a worse progno-
sis. The follicular lymphoma international prognostic index 
(FLIPI),1 FLIPI‐2,2 and the molecular FLIPI (m7‐FLIPI)3 
are clinical and biologic prognostic indices that have been 
associated with 5‐ and 10‐year OS in newly diagnosed FL 
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Abstract
Follicular lymphoma (FL) patients treated with firstline R‐CHOP who experience 
progression of disease (POD) within 2 years have a shorter survival than those who 
do not have POD within 2 years. Whether this observation holds for patients treated 
initially with biologic immunotherapy alone is unknown. We performed a retrospec-
tive analysis of 174 patients pooled from three frontline rituximab (R)‐based 
nonchemotherapy doublet trials: R‐galiximab (Anti‐CD80, CALGB 50402), R‐
epratuzumab (Anti‐CD22, CALGB 50701), and R‐lenalidomide (CALGB 50803) to 
determine outcomes of early progressors and risk factors for early POD, defined as 
progression within 24 months from study entry. Twenty‐eight percent (48/174) of 
patients had early POD. After adjusting for the Follicular Lymphoma International 
Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS 
compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 
1.50‐12.5), P = 0.007). For early POD, the 2‐year survival was 80% vs 99% for non-
early POD, and the 5‐year survival was 74% vs 90%, respectively. These findings 
suggest that the adverse survival of patients with early POD may be independent of 
initial treatment modality.
K E Y W O R D S
biologic agents, early progression, follicular lymphoma, immunotherapy, PFS24
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patients and have been traditionally used to estimate survival 
in newly diagnosed patients. Recently, several studies have 
also identified early relapse after firstline chemotherapy to be 
associated with poor OS.
In the National LymphoCare Project, progression of 
disease (POD) within 24 months of diagnosis was recently 
identified as an important prognostic factor for patients 
with FL treated with firstline R‐CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone).4 Progression of 
disease (POD) within 2 years of diagnosis was associated 
with and increased risk of death [hazard ratio (HR) 6.4] and 
a 50% 5‐year overall survival (OS), compared to a 90% 5‐
year OS in patients who did not relapse within 2 years. This 
finding was validated in patients treated with rituximab, 
fludarabine, mitoxantrone, and dexamethasone (R‐FND).4 
The German Low‐Grade Lymphoma study group and the 
British Columbia Cancer Agency also validated this find-
ing among R‐CHOP and R‐CVP‐treated patients who pro-
gressed within 2 years of diagnosis.5 Taken together, these 
three studies confirm that progression within 2 years from 
diagnosis is associated with inferior OS in FL patients 
treated with rituximab‐containing combination chemother-
apy. As a result of the similar findings from these trials, a 
large retrospective international study validated event‐free 
survival (EFS) at 24 months from diagnosis as relevant sur-
rogate endpoint for OS in patients with FL initially treated 
with R‐containing chemotherapy.6
Not all patients require or can tolerate chemoimmunother-
apy, and there are acute and long‐term toxicities associated 
with traditional chemotherapy such as CHOP, FND, and ben-
damustine. Thus, studies have evaluated noncytotoxic strat-
egies for initial treatment of patients with FL. For example, 
E4402 (RESORT) enrolled untreated low‐tumor burden FL 
to single‐agent rituximab for four doses followed by either 
re‐treatment rituximab (RR) as needed or maintenance ritux-
imab (MR).7 This study demonstrated that rituximab admin-
istered in an RR strategy is as efficacious as MR in low‐tumor 
burden FL with a 3‐year PFS of 65% vs 73%, respectively.7 
SAKK35/98 comparing short course and extended rituximab 
dosing reported a 66% 2‐year PFS in the extended dosing 
arm.8 In a study from the United Kingdom, FL patients were 
randomly assigned to watch‐and‐wait or rituximab induction 
plus MR for 2 years. The primary endpoint was time to next 
treatment, and rituximab‐treated patients were far less likely 
to require new therapy at 3 years (88% vs 46%).9 Whether 
the early event status such as the progression‐free survival at 
24 months (PFS24) from these trials can inform subsequent 
overall survival in patients treated without chemotherapy is 
unknown.
The Cancer and Leukemia Group B (CALGB) (now 
known as Alliance for Clinical Trials in Oncology) con-
ducted a series of phase II studies to explore novel frontline 
rituximab (R)‐based nonchemotherapy doublets for patients 
with previously untreated FL from 2005 to 2011.10-12 In 
CALGB 50402, 61 patients bulky stage II or stage III‐IV 
grade 1‐3a FL were treated with 4 weekly doses of rituximab 
and galiximab (anti‐CD80 monoclonal antibody) followed 
by four additional doses of the combination every 2 months. 
With this combination, the overall response (OR) rate was 
72.1%, with 47.6% complete responses (CR) and median 
PFS of 2.9 years.10 In CALGB 50701, 59 patients with bulky 
stage II or stage III‐IV grade 1‐3a FL were treated with com-
bined rituximab and epratuzumab (anti‐CD22 monoclonal 
antibody) utilizing a similar schedule to CALGB 50402 with 
4 weekly doses of the combination followed by four addi-
tional doses every 2 months. With rituximab‐epratuzumab, 
the OR was 88.2% with 42.4% CRs and a median PFS of 
3.5 years.11 Lastly, CALGB 50803 examined the doublet 
combination of rituximab and lenalidomide; however, un-
like the previous two trials, this study restricted eligibility to 
those patients with previously untreated grade 1‐3a FL with 
FLIPI scores of 0‐2. In this study, rituximab was adminis-
tered weekly for four weeks during cycle 1 and then every 
2 months for 4 additional doses with lenalidomide 20 mg 
days 1‐21 of a 28‐day cycle for up to 12 cycles. In 65 patients 
treated with rituximab and lenalidomide, the ORR was 93%, 
CR was 72%, and median PFS is not reached.12 With these 
differing immunotherapy combination regimens in a similar 
previously untreated FL patient population, the 2‐year PFS 
were 58%, 74%, and 86%, for CALGB 50402, 50701, and 
50803, respectively.
In the current analysis, we performed a retrospective 
pooled analysis of patients enrolled on these 3 phase II trials, 
and evaluated if PFS24 could be used as a prognostic tool 
after initial biologic treatment. In addition, we identified risk 
factors for early progression of disease after treatment with 
these biologic doublets.
2 |  METHODS
Early POD was defined as progression within 24 months 
from study entry. Patients with early POD or non‐progres-
sors with at least a two‐year follow‐up from study entry were 
Key Points
In this combined analysis of three CALGB clinical 
trials, patients with early progression of follicular 
lymphoma following frontline immunotherapy dou-
blets are at increased risk of death. PFS24 is a prog-
nostic marker for overall survival in patients treated 
with rituximab‐containing immunotherapy.
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included. Clinical trials CALGB 50402, 50701 and 50803 
had similar eligibility criteria: previously untreated follicular 
lymphoma, grade 1, 2, or 3a with stage III, IV, or bulky (sin-
gle mass >7 cm) stage II disease, and ECOG PS 0 to 2. Of 
note, while CALGB 50402 and 50701 allowed patients with 
FLIPI scores of 0‐5, CALGB 50803 was restricted to patients 
with FLIPI scores of 0‐2.
Univariable and multivariable logistic regression model-
ing using forward selection was performed to identify predic-
tors of early POD. Kaplan‐Meier (KM) method was used to 
estimate 2‐year and 5‐year overall survival probability.13 As 
POD status is not known at time of study entry or diagnosis, 
to avoid a 2‐year survival bias for the reference group, sur-
vival is measured from a risk‐defining event: date of POD for 
early progressors and two years following study entry or di-
agnosis for the reference group. Hazard ratios (HR) and 95% 
CI were calculated using a univariable and multivariable Cox 
regression model adjusting for FLIPI. Because the definition 
of early POD in our analysis was time of study entry onto 
these therapeutic trials until disease progression, and was 
not the same definition as early POD used in the National 
LymphoCare, R‐FND and German Low‐Grade Lymphoma 
trials, which was time from diagnosis until progression, we 
also determined the association of POD within 24 months 
from the diagnosis of follicular lymphoma with survival in 
patients on these 3 CALGB trials.
We examined risk factors for age >60 years, hemoglo-
bin <10 g/dL, number of lymph node sites >4, stage III/IV, 
lactate dehydrogenase (LDH) above normal, bone marrow 
involvement, lymph node size >6 cm, beta‐2 microglobu-
lin >normal, and grade 3a disease. In addition, male or fe-
male sex, B symptoms, and albumin <3.5 were analyzed. 
Continuous variables white blood cell count (WBC) at di-
agnosis, absolute lymphocyte count (ALC), and absolute 
monocyte count (AMC), and ALC/AMC ratio were also 
considered. Lastly, we examined pathology features Ki‐67, 
CD68, FOXP3, PD1, PDL1, and interfollicular CD10 as done 
by Sohani et al.14
Using these risk factors, we developed a multivariable lo-
gistic model for early progression. Due to the limited sample 
size, a cross‐validation method (fivefold) was used for vali-
dation. Once this cross‐validation procedure was complete, 
the final logistic model was fitted using the whole data set.
Data collection and statistical analyses were conducted 
by the Alliance Statistics and Data Center. All analyses 
were based on the study database frozen as follows: CALGB 
50402 on April 4, 2011, 50701 on April 17, 2012, and 50803 
on May 29, 2014.
3 |  RESULTS
3.1 | Patient characteristics
Sixty patients on CALGB 50402, 57 from CALGB 50701, 
and 57 from CALGB 50803 were included. Patient charac-
teristics from the individual studies are shown in Table 1. 
The median age was 54, and 49.4% were male. For the entire 
group, FLIPI low, intermediate, and high was 24%, 52% and 
T A B L E  1  Patient characteristics
Variable
Overall 
N = 174
50402 
N = 60
50701 
N = 57
50803 
N = 57 P‐value*
Sex
Male 86 (49.4%) 36 (60.0%) 23 (40.4%) 27 (47.4%) 0.10
Female 88 (50.6%) 24 (40.0%) 34 (59.7%) 30 (52.6%)
Age (years)
Median (Range) 54 (22‐90) 57 (22‐85) 54 (32‐90) 52 (32‐79) 0.25
FLIPI
Low 42 (24.4%) 12 (20.7%) 13 (22.8%) 17 (29.8%) <0.01†
Intermediate 89 (51.7%) 25 (43.1%) 26 (45.6%) 38 (66.7%)
High 41 (23.8%) 21 (36.2%) 18 (31.6%) 2 (3.51%)
Early progression
No 126 (72.4%) 35 (58.3%) 42 (73.7%) 49 (86.0%) 0.0036
Yes 48 (27.6%) 25 (41.7%) 15 (26.3%) 8 (14.0%)
Median follow‐up in years 
(Range)
n = 185 n = 61 n = 59 n = 65 <0.0001†
5.4 (0.0‐10.1) 6.7 (0.0‐10.1) 6.3 (0.3‐8.1) 4.5 (0.1‐5.5)
Median time diagnosis to 
enrollment in months (Range)
n = 169 
1.94 (0.20‐115)
*Compares variables across studies 
†Statistically significant, α = 0.05 
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24%, respectively. Of note, CALGB 50803 had only 3.5% 
high‐risk FLIPI since the study was designed to exclude high‐
risk FLIPI patients. Median follow‐up time was 5.4 years 
(range 0‐10.1 years) and was shortest in the CALGB 50803 
study, 4.5 years (range 0.9‐5.5 years). The median time from 
diagnosis to study entry was 1.94 months (0.20‐115 months).
Of the 174 patients, 48 (28%) had a relapse of lymphoma 
within 24 months of study entry. In our secondary analysis 
using time from diagnosis, 29 of 171 (17%) patients had re-
lapse of lymphoma within 24 months of diagnosis. Three pa-
tients did not have the diagnosis date available.
Of the 48 early progressors, the median age was 57, 40.4% 
were intermediate‐risk FLIPI, 46.8% were high‐risk FLIPI, 
and 38.3% had bulky disease ≥7 cm. Twenty‐five (41.7%), 
15 (26.3%), and 8 (14%) of the early progressors came from 
CALGB 50402, 50701, and 50803 studies, respectively. 
The median follow‐up time of the early progressors was 
5.1 years (range 0‐8.1 years) compared to 5.4 years (range, 
0‐10.1 years) for the entire cohort, which is likely a reflection 
of overall survival. Additional patient characteristics of early 
progressors are shown in Table 2.
3.2 | Early POD and survival
Patients with early POD from study entry (n = 48) had a 2‐
year OS of 80% (95% CI 66%‐89%) and 5‐year OS of 74% 
(95% CI 58%‐85%) compared to 99% and 90%, respectively, 
for patients without early POD (n = 126). Of the 48 patients 
with early POD, 12 (25%) have died during subsequent fol-
low‐up, compared to 7 (5.6%) of the reference group. The 
Kaplan‐Meir curve of OS showed an inferior overall survival 
for patients with early POD compared to those not relaps-
ing within 24 months(P < 0.001) [Figure 1]. Early POD from 
study entry was associated with an increased risk of death 
with a HR of 4.05 (95% CI 1.57‐10.5, P = 0.004). Even after 
adjusting for FLIPI, early POD from study entry was associ-
ated with an increased risk of death with an HR of 4.33 (CI: 
1.50‐12.5, P = 0.007) [Table 3].
When early progression was defined from the time of di-
agnosis until progression, with 29 early progressors in this 
group compared to 142 patients without early progression, 
the results were similar. The 2‐ and 5‐year OS were 78% (95% 
CI: 57%‐89%) and 69% (95% CI 48%‐83%) for early POD 
from diagnosis compared to 2‐ and 5‐year OS of 99% and 
93% in those patients without early progression from diagno-
sis. The HR for OS was 4.10 (95% CI 1.52‐11.0), P = 0.005 
[Data not shown].
3.3 | Risk Factors associated with early POD
For patients experiencing early POD, univariable analysis 
showed that clinical factors at study entry which predicted 
early POD and inferior overall survival were age, male sex, 
hemoglobin <10 g/dL, number of nodal sites >4, elevated 
LDH, FLIPI, lymph node size ≥7, albumin <3.5 g/dL, and 
interfollicular expression of CD10 by immunochemistry. By 
univariable analysis, hemoglobin, FLIPI 3‐5, and albumin 
were most highly associated with early progression, odds 
ratio of 11.36, 6.95, and 5.32, respectively (Table 2). In mul-
tivariable analysis, clinical factors predictive of early POD 
were male sex, albumin <3.5 g/dL, low absolute monocyte 
count (AMC), interfollicular CD10 expression, and FLIPI 
(Table 4). The biologic features of Ki‐67, CD68, FOXP3, 
PD1, and PDL1 expression did not correlate with early POD.
4 |  DISCUSSION
In the present study, POD within 2 years after study entry in 
patients receiving frontline rituximab‐based biologic noncy-
totoxic therapy is associated with an inferior survival. To our 
knowledge, this is the first study of firstline immunotherapy 
regimens to evaluate the association of early progression 
with survival.
The 2‐year progression‐ and event‐free survival (PFS24 
or EFS24) from diagnosis is becoming established as an 
important dynamic prognostic tool for patients.4-6 Similar 
to the LymphoCare,4 the German Low‐Grade Lymphoma 
Study Group (GLSG), and British Columbia Cancer Agency 
(BCCA) analysis of frontline follicular lymphoma patients,5 
17% of our patients had POD within 24 months from diagno-
sis and 5‐year OS was 69% in this group.
We also evaluated POD from study entry in these trials. 
Date of study entry was a more robust and accurate time‐
point in patients enrolled on these 3 CALGB studies, whereas 
date of diagnosis may have been less accurate in patients who 
were initially observed without therapy for several months 
or years until study enrollment. When evaluating the PFS24 
from study entry in our analysis, 28% of patients met the 
early POD criteria, and 5‐year OS was 74% in this group, 
similar to the OS in patients with early POD defined as from 
the date of diagnosis to progression. Our results show that 
both PFS24 from date of diagnosis and from date of study 
entry are associated with overall survival.
In multivariable analysis, male sex, high FLIPI, low al-
bumin, low absolute monocyte count, and interfollicular 
CD10 staining were all associated with early POD. The as-
sociation of male sex with early POD and subsequent worse 
OS suggests a different biology of follicular lymphoma and 
different pharmacokinetics of rituximab in males compared 
to females.15 Hypoalbuminemia and low absolute monocyte 
count have been correlated with prognosis in other studies in 
FL.16,17 We hypothesize that FL behaves more aggressively 
in patients with lower monocyte immunity, perhaps by sup-
pression of monocytes by the lymphoma itself. Lastly, in-
terfollicular CD10 by immunohistochemistry was identified 
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T A B L E  2  Characteristics of patients with early progression and univariable analysis
Variable Overall
Early progression
OR (95% CI) PNo Yes
Age (years) n = 174 n = 126 n = 48
Median 54 53 57 1.03 (1.00, 1.06) 0.0300
Range (22‐90) (22‐83) (32‐90)
Age (years)
0‐59 121 (69.5%) 94 (74.6%) 27 (56.3%) ‐ 0.0187
60+ 53 (30.5%) 32 (25.4%) 21 (43.8%) 2.28 (1.14, 4.59)
Sex
Male 86 (49.4%) 53 (42.1%) 33 (68.8%) 3.03 (1.50, 6.13) 0.0017
Female 88 (50.6%) 73 (58.0%) 15 (31.3%) ‐
Hemoglobin (g/dL)
<10 5 (2.87%) 1 (0.79%) 4 (8.33%) 11.36 (1.24, 104) 0.0209
≥10 169 (97.1%) 125 (99.2%) 44 (91.7%) ‐
Number of nodal sites
≤4 70 (40.5%) 58 (46.4%) 12 (25.0%) 0.0102
>4 103 (59.5%) 67 (53.6%) 36 (75.0%) 2.60 (1.24, 5.45)
Stage of Disease
Stage I‐II 11 (6.36%) 8 (6.35%) 3 (6.38%) 1.01 (0.26, 3.96) 1.0000
Stage III‐IV 162 (93.6%) 118 (93.7%) 44 (93.6%) ‐
LDH
Below ULN 154 (88.5%) 117 (92.9%) 37 (77.1%) ‐ 0.0035
Above ULN 20 (11.5%) 9 (7.14%) 11 (23.0%) 3.86 (1.49, 10.0)
Bone Marrow involvement
No 86 (49.4%) 64 (50.8%) 22 (45.8%) ‐ 0.5586
Yes 88 (50.6%) 62 (49.2%) 26 (54.2%) 1.22 (0.63, 2.38)
Node Size (cm)
<7 130 (77.8%) 101 (84.2%) 29 (61.7%) ‐ 0.0017
≥7 37 (22.2%) 19 (15.8%) 18 (38.3%) 3.30 (1.53, 7.09)
Beta‐2‐Microglobulin
Below ULN 30 (60.0%) 27 (62.8%) 3 (42.9%) ‐ 0.4161
Above ULN 20 (40.0%) 16 (37.2%) 4 (57.1%) 2.25 (0.45, 11.4)
Grade 3a Disease
No 160 (94.1%) 114 (92.7%) 46 (97.9%) 3.63 (0.45, 29.5) 0.2874
Yes 10 (5.88%) 9 (7.32%) 1 (2.13%) ‐
B symptoms Present
No 153 (91.6%) 111 (91.0%) 42 (93.3%) 1.39 (0.37, 5.22) 0.7611
Yes 14 (8.38%) 11 (9.02%) 3 (6.67%) ‐
Albumin (g/dL)
<3.5 10 (8.70%) 3 (3.95%) 7 (18.0%) 5.32 (1.29, 21.9) 0.0299
≥3.5 105 (91.3%) 73 (96.1%) 32 (82.1%) ‐
WBC at baseline (×109 
per liter)
n = 171 n = 123 n = 48
Median 6.3 6.4 6 1.09 (0.99, 1.21) 0.095
Range (2.7‐77.8) (2.7‐16.3) (3.8‐77.8)
(Continues)
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by Fouad‐Younes et al18 as correlating with OS in FL, and 
this study confirms these findings, specifically associating 
it with early POD as well. The presence of CD10+ B‐cells 
in the interfollicular zones could indicate a more aggres-
sive disease with extension beyond the follicles. The other 
immunochemistry markers studied, such as PD1 and FoxP3, 
did not separate a group more prone to early POD. In fact, it 
was previously reported that rituximab may circumvent the 
prognostic significance of these IHC markers.19 More inves-
tigation into the molecular and genetic biology of early POD 
FL is still needed and may ultimately help to identify these 
high‐risk patients at diagnosis.
Although eligibility criteria were mainly uniform, 
this study is limited by the heterogeneity of treatments of 
Variable Overall
Early progression
OR (95% CI) PNo Yes
ALC at baseline (×109 
per liter)
n = 168 n = 121 n = 47
Median 1.38 1.4 1.26 1.16 (0.96, 1.39) 0.1169
Range (0.43‐41.2) (0.43‐10.1) (0.45‐41.2)
AMC at baseline (×109 
per liter)
n = 168 n = 121 n = 47 0.0595
Median 0.45 0.44 0.52 4.3 (0.94, 19.6)
Range (0.01‐3.04) (0.01‐1.00) (0.18‐3.04)
ALC/AMC ratio n = 168 n = 121 n = 47
Median 3.07 3.15 2.78 1.03 (0.98, 1.08) 0.2963
Range (0.83‐57) (0.83‐57) (0.85‐53)
FoxP3
Diffuse 94 (74.0%) 70 (76.9%) 24 (66.7%) ‐ 0.3033
Follicular 3 (2.36%) 1 (1.10%) 2 (5.56%) 5.83 (0.51, 67.2)
M 20 (15.8%) 14 (15.4%) 6 (16.7%) 1.25 (0.43, 3.62)
Partial 10 (7.87%) 6 (6.59%) 4 (11.1%) 1.94 (0.51, 7.48)
PD1
≤5% 29 (31.2%) 22 (32.4%) 7 (28.0%) 3.82 (0.42, 34.8) 0.1685
6%‐33% 51 (54.8%) 34 (50.0%) 17 (68.0%) 6.00 (0.72, 50.1)
>33% 13 (14.0%) 12 (17.7%) 1 (4.00%) ‐
FLIPI
Low 42 (24.4%) 36 (28.8%) 6 (12.8%) ‐ <0.0001
Intermediate 89 (51.7%) 70 (56.0%) 19 (40.4%) 1.63 (0.60, 4.44)
High 41 (23.8%) 19 (15.2%) 22 (46.8%) 6.95 (2.41, 20.1)
Ki67 n = 102 n = 72 n = 30
Median 9.24 9.69 8.92 0.99 (0.95, 1.03) 0.5553
Range (0.51‐67.5) (0.51‐67.5) (0.59‐39.9)
CD10 (interfollicular)
Negative 35 (35.4%) 30 (42.9%) 5 (17.2%) ‐
Positive 64 (64.7%) 40 (57.1%) 24 (82.8%) 3.60 (1.23, 10.5) 0.0153
Diagnosis to Enroll 
(Month)
n = 169 n = 123 n = 46
Median 1.94 2 1.87 1.00 (0.99, 1.03) 0.4231
Range (0.20‐115) (0.26‐115) (0.20‐103)
Survival Follow‐up 
(Years)
n = 174 n = 126 n = 48
Median 5.4 5.5 5.1 0.77 (0.63, 0.94) 0.0093
Range (0.0‐10.1) (2.1‐10.1) (0.0‐8.1)
T A B L E  2  (Continued)
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rituximab‐containing “doublets.” Both galiximab and epratu-
zumab are no longer being developed, and it is unclear what 
benefit was gained with these combinations compared to sin-
gle‐agent rituximab. In single‐agent rituximab studies such 
as the RESORT and the SAKK35/98 studies, 25%‐33% have 
relapsed or progressed within 2‐3 years.7,8 When compared 
to the 42% early progression rates with R‐galiximab and 26% 
in the R‐epratuzumab trial, the early relapse rates with single‐
agent rituximab appear similar or even lower, suggesting that 
the anti‐CD80 and anti‐CD22 antibodies added little and may 
have even adversely impacted the efficacy of rituximab, al-
though the study population on these two doublet trials likely 
had higher risk FLIPI scores at enrollment. Therefore, al-
though these two antibodies are no longer utilized to treat FL, 
the 26%‐42% rates of early progression observed with these 
immunotherapy combinations are likely similar to the rates 
of early progression observed in patients treated with ritux-
imab alone. As a result, this study suggests that inferior OS 
(5‐year OS 74%) is also expected in FL patients progressing 
within 24 months of firstline single‐agent rituximab, similar 
although perhaps not quite as poor as the inferior outcomes 
(5‐year OS of 50%) observed in early progressors after R‐
CHOP, R‐CVP, and R‐FND.4-6
On this trial, the numbers of early progressors from the 
R‐galiximab (42%, CALGB 50402) and R‐epratuzumab 
(26%, CALGB 50701) studies were higher than observed 
with R‐lenalidomide (14%, CALGB 50803) and R‐CHOP 
(19%, National LymphoCare Study4), perhaps in part due 
to variability in the FLIPI scores of the patients enrolled on 
these trials, the variability in histology (FL grade 1‐2 vs 3), 
and the intensity of initial treatment. The number of high‐risk 
patients with FLIPI scores of 3‐5 was 37.3%, 30.5%, 3.5%, 
and 44% on CALGB 50402, CALGB 50701, CALGB 50803, 
and the National LymphoCare Study, respectively. Both the 
National LymphoCare Study and this study did demonstrate 
an association with high‐risk FLIPI score and early progres-
sion. Additionally, CALGB 50402, 50701, and 50803 all 
restricted enrollment of patients to grade 1‐2 or 3a FL at di-
agnosis. In the National LymphoCare study, transformed FL 
was excluded; however, FL grade 3 patients including 3a and 
3b subtypes were enrolled. Thirty‐eight percent of patients on 
F I G U R E  1  Overall survival (separate TIFF file)
Overall Survival (Univariable)
Overall Survival (Multivariable)
FLIPI +Early progression
HR (95% CI) P‐value HR (95% CI) P‐value
Early progression Early progression
No ‐ 0.0039 No ‐ 0.0068
Yes 4.05 (1.57, 10.5) Yes 4.33 (1.50, 12.5)
FLIPI 0.6965
Low ‐
Intermediate 0.79 (0.20, 3.20)
High 1.27 (0.31, 5.19)
T A B L E  3  Hazard ratio of overall 
survival
Variable Description Odds Ratio (95% CI) P‐value
Sex Male vs Female 7.93 (1.5‐41.66) 0.015
Albumin <3.5 vs ≥3.5 17.51 (0.97, 315.27) 0.052
AMC 1 unit decrease 41.7 (0.91, >999) 0.056
Interfollicular CD10 Positive vs Negative 11.06 (1.74‐70.41) 0.011
FLIPI Intermediate vs Low 2.21 (0.20‐24.17) 0.096
High vs Low 10.35 (0.75‐142.85)
T A B L E  4  Multivariable Analysis of 
risk factors associated with early POD
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the National LymphoCare Study had grade 3 disease, com-
pared to 5%‐10% of patients on the CALGB trials. As some 
patients with grade 3 disease may have prolonged remissions 
with anthracycline‐based treatment, it is possible treatment 
with R‐CHOP resulted in fewer early progressors than ob-
served with the less intensive regimens in this subgroup. 
Lastly, the limited efficacy of the galiximab and epratuzumab 
compared to lenalidomide or CHOP also likely resulted in 
more early progressions on CALGB 50402 and 50701 than 
observed with R‐lenalidomide or RCHOP. Overall, although 
more patients experienced early progression with immu-
notherapy than observed with R‐chemotherapy, this trial 
demonstrates that even with less intensive immunotherapy, 
the application of PFS24 predicts overall survival and vali-
dates the use of this prognostic indicator across clinical trial 
settings for patients with FL.
Optimal treatment approaches for follicular lymphoma 
patients that progress within 2 years are not known. For early 
progressors after R‐chemotherapy, the role of high‐dose ther-
apy (HDT) with autologous stem cell rescue for early pro-
gressors has not been well studied but is a commonly used 
strategy. Although HDT with autologous stem cell rescue can 
be an effective strategy for salvage,20 other less aggressive op-
tions may be as effective including new CD20 targeted agents 
such as obinutuzumab, and biologic agents, such idelalisib, 
copanlisib, or lenalidomide. The US National Clinical Trials 
Network recently activated the clinical trial S1608 to evaluate 
three different approaches for patients with a first relapse of 
FL within 24 months of completion of bendamustine‐based 
immunochemotherapy (with anti‐CD20 antibody therapy). In 
this Phase II trial, patients are randomized to obinutuzumab 
+CHOP, obinutuzumab +lenalidomide, or obinutuzumab 
+TGR1202 (a novel PI3K inhibitor). Hopefully, the results 
of this trial will clarify whether a more aggressive second‐
line conventional immunochemotherapy approach or a novel 
targeted therapy approach is better for patients with early pro-
gression after immunochemotherapy.
In addition to better treatment options, identification of 
patients at risk for early POD is also needed. Assessment 
for minimal residual disease (MRD) using next‐genera-
tion sequencing (NGS) has shown early utility in follicular 
lymphoma.21 Biologic risk assessment at diagnosis using 
methods such as the m7 FLIPI may also help identify these 
patients at diagnosis and permit examination of novel front-
line therapeutic approaches in this high‐risk group.
In summary, early POD within 2 years of study entry in 
our patient cohort treated with upfront rituximab doublets 
defines a subgroup of patients who are at greater risk of 
death. This combined analysis, coupled with the National 
LymphoCare Study, the German Low‐Grade Study Group 
and British Columbia Cancer Agency, and the Maurer EFS24 
cohorts validate PFS24 as an important prognostic marker in 
FL regardless of initial treatment.
ClinicalTrials.gov: NCT00117975 (CALGB 50402), 
NCT00553501 (CALGB 50701), and NCT01145495 
(CALGB 50803).
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